Expediting Development of Biologics in China: From Strategy to Regulatory Expectations and Beyond

Addressing "availability and affordability" of novel biologics will be the focus of China's life science industry in the foreseeable future. Few biologic drugs are currently available in China, despite the increasing...

WuXi SVP Rich Soll to Provide Perspectives on Oursourcing at China Forum

The fourth China Forum kicks off in Vienna, Austria next month, with WuXi senior vice president Richard Soll among the speakers. In his presentation, Soll will provide a snapshot of contract...

WuXi CFO Edward Hu to Discuss VC Funding at BIO China

WuXi CFO Edward Hu will share his thoughts on early-stage venture capital funding at BIO China in November. As head of WuXi Corporate Venture Fund, Hu pays close attention to the...

WuXi SVP Chris Chen to Deliver Keynote Speech at IBC’s BioProcess International China...

WuXi  executive Dr. Chris Chen is to deliver the keynote speech at IBC’s BioProcess  International China Conference in August. Chen, Senior Vice President  and Chief Technology Officer, Biologics Services at WuXi,...

WuXi Global Webinar – “Demystifying Product Development in China”

Overview China’s fast growing healthcare market represents a significant opportunity for pharmaceutical and biotechnology companies to develop and launch therapies. By capitalizing on local research, development, manufacturing, and regulatory know-how, companies can design and...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

Cyclica CEO Naheed Kurji Says AI Could Create a New Paradigm...

Toronto-based Cyclica President and CEO Naheed Kurji acknowledges that artificial intelligence (AI) is a transformative technology, but he contends it is not the “silver...